Zacks.com on MSN2d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...
FierceBiotech3d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
pharmaphorum3d
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...
The Pharma Letter3d
GSK’s depemokimab scores well in CRSwNP trials
UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...
Daily5d
Twice-Yearly Depemokimab Effectively Lowers Exacerbation Rates in Severe Eosinophilic Asthma: Study Reveals
The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...
Pharmabiz3d
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...
Yahoo Finance2d
GSK’s depemokimab shows promise in Phase III trials for chronic rhinosinusitis
UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...
London South East4d
Positive results of ANCHOR trials of depemokimab
Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks · Depemokimab is an ultra-long-acting ...